Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3574137 A
Publication typeGrant
Publication dateApr 6, 1971
Filing dateFeb 25, 1969
Priority dateFeb 25, 1969
Also published asDE2008493A1, DE2008493B2, DE2008493C3
Publication numberUS 3574137 A, US 3574137A, US-A-3574137, US3574137 A, US3574137A
InventorsDecasperis Anthony J
Original AssigneePfizer
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Multiple-analysis hematology control comprising human red blood cells and fowl red blood cells in an anticoagulant containing human serologically compatible plasma medium
US 3574137 A
Abstract  available in
Images(3)
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States Patent 3,574,137 MULTIPLE-ANALYSIS HEMATOLOGY CONTROL COMPRISING HUMAN RED BLOOD CELLS AND FOWL RED BLOOD CELLS IN AN ANTICOAGU- LANT CONTAINING HUMAN SEROLOGICALLY COMPATIBLE PLASMA MEDIUM Anthony J. Decasperis, Elmhurst, N.Y., assignor to Pfizer Inc., New York, N.Y. N0 Drawing. Filed Feb. 25, 1969, Ser. No. 802,263 Int. Cl. G01n 33/16 US. Cl. 252-408 9 Claims ABSTRACT on THE DISCLOSURE A diagnostic composition serving as a multiple-analysis hematology reference control for red blood cell and white blood cell counting, hemoglobin content and hematocrit determination.

BACKGROUND OF THE INVENTION This invention relates to a diagnostic hematology composition. More particularly, it relates to a stabilized and standardized suspension of blood cells that provides a reference control for a number of routine hematologic determinations.

Up to now, the prior art of hematology determinations has suffered from the lack of stable reference controls. With the advent of automated devices capable of performing multiple hematological determinations, a growing need has developed for cross-reference samples for manual and automated machine analyses.

The distinguishing feature of this invention resides in the preparation of a stable multiple-analysis reference control which combines in a single composition reference controls for red blood cell and white blood counting, hemoglobin content, hematocrit determination, and allows by mathematical computation, the calculation of mean corpuscular volume and mean corpuscular hemoglobin concentration, and mean corpuscular hemoglobin.

An embodiment of this invention is the preparation of a stable cell suspension that approximates the composition of normal human blood. Oxalated or citrated whole human blood has limited stability on storage. Red blood cells slowly hemolyze and undergo changes in size and shape. Similarly, white blood cells suffer degenerative changes.

A novel feature of this invention is the preparation of a stable red blood cell suspension that serves as a reference control for human white blood cells. Human white blood cells are not suitable for control purposes, especially in the presence of red blood cells, because they are unstable, excreting a lysozyme type of enzyme that attacks red blood cells. Avian red blood cells are larger than human red blood cells, and approximate the size and shape of human white blood cells. For purposes of this invention it has been found that fowl red blood cells such as goose, chicken, duck, and preferably turkey red blood cells, close- 1y match the size and shape of human white blood cells, and lend themselves nicely to the subject tanning process. These stabilized simulated white blood cells provide a satisfactory substitute for human white blood cells in our composition control product.

It has been found that fresh human red blood cells, stabilized by suspension in human plasma or serum with added metabolic preservative, satisfactorily provide the red blood cells component of the subject composition. Plasma or serum provide some of the necessary electrolytes and proteins necessary for red blood metabolic stability. Selected purines or pyrimidines act as additional metabolic preservatives. The untauned red blood cells are readily hemolyzed in the prior operational step for the white blood cell count and subsequent hemoglobin determination.

Suspensions of human red blood cells and simulated white blood cells are mixed in such proportion that the final red blood cell and white blood cell counts, hemoglobin content and hematocrit fall in the range considered normal for human blood.

The normal range in human blood for red blood cells is 4,000,000-5,000,000 cells/mm. and for white blood cells the count is 5,000l0,000 cells/mmfi. The normal hemoglobin value is l2-16 grams/ ml. The term hematocrit is defined as the ratio of volume of packed red blood cells to the volume of whole blood. The normal ratio in humans is about 45%. The means corpuscular volume is the ratio of the volume of packed red cells in ml. per liter of blood to red blood cells in millions per cubic millimeter. The mean corpuscular hemoglobin concentration is an index indicating the mean or average weight of hemoglobin per 100 ml. of packed red blood cell in terms of percent. The mean corpuscular hemoglobin is the ratio of hemoglobin content in grams per liter to red blood cells in millions per cubic millimeter.

It is evident that a control product must accurately indicate on a comparative basis what a test sample of blood constitutes with regard to the above determinations. It is further evident how important it is for the control product to simulate non-treated cells. It follows, for instance, that if the control product contains cells that differ materially in size, the experimental results will be inaccurate, if not wholly meaningless. In essence, the cells treated by the method disclosed herein provides an excellent system of checks and balances so necessary in hematologic determinations.

SUMMARY OF THE INVENTION In general, this invention embodies a composition prepared by mixing a suspension of human red blood cells with a suspension of stabilized fowl red blood cells (simulated human white blood cells) in such proportions as to provide in a single composition a multiple-analysis reference control for red blood cell and white blood cell counting, hemoglobin content and hematocrit determination.

DETAILED DESCRIPTION OF THE INVENTION Regarding the novel methods to be described, it is to be understood that the term saline throughout can be any of the following three solutions: 0.9% by weight aqueous sodium chloride solution which is designated by the term solution A; 0.45% by weight aqueous sodium chloride solution designated as solution B; or a buffered saline solution (solution C). In the preparation of the simulated white blood cell control, it is important to use the 0.45% solution (solution B) for the reason that this concentration advantageously tends to modify the normal shape of fowl red blood cells which are oval to a more circular shape like human white blood cells.

The first step of the herein disclosed method for stabilizing fowl red blood cells consists of suspending the red cells in saline to provide up to a 50% volume suspension. Although a concentration as high as 50% will work, it is preferred to use a range from about 5% to about 10% by volume, and even more preferred to use an 8% suspension. This suspension is combined with an equal volume of a 1 to 3% solution by weight of mercuric chloride in saline.

The second step consists of heating the resulting mixture at 37 C. for at least 12 hours, and preferably for about 19-20 hours. The solid materials are recovered by centrifugation and separation, and then resuspended in saline, as a 2-6%, and preferably a 4% suspension.

The third step consists of combining with the aforesaid suspension, an equal volume of a 0.0025% w./v. solution of aqueous tannic acid in saline with thorough mixing,

3 incubating the resulting mixture, and recovering the solid mixture by centrifugation and separation. The saline solution containing the tannic acid is a buffered saline solution having a pH of 7.2, and is the solution C referred to earlier. Its preparation consists of the following reagents in the proportions indicated (per liter).

M1. 0.9% saline 500 0.15 M disodium phosphate 385 0.15 M potassium phosphate 115 The tanned cells are washed several times with saline, and then reconstituted in sterile Alsevers solution.

The preparation of the human red blood cell suspension is carried out under sterile conditions. For this purpose, red blood cells from any blood type can be used. However, Group blood cells are preferably used because of the ready availability of blood donors of this type. Pooled Group 0 blood, collected in acid citrate-dextrose anticoagulant solution, is centrifuged, and the supernatant removed and set aside, and the buffy layer of white blood cells gently removed and discarded. The packed red blood cells are washed several times with Alsevers solution, reconstituted in Alsevers solution, and stored at 2-8 C.

The resuspending medium, used for the final suspension of the human red blood cells, is prepared from defibrinated plasma that is serologically compatible with the suspended human red blood cells, i.e., Group A cells with plasma from Group A, Group B cells with plasma from Group B and Group 0 cells with plasma from Group 0. Defibrinated Group AB plasma (lacking antigens A and B) is compatible with Group A, Group B and Group 0 red blood cells. These plasma supernatants are defibrinated by treatment with bovine thrombin and then diluted 1:3 with Alsevers solution.

As a further stability aid for the fresh blood cells component of the final cell suspension, a metabolic preservative, selected from the class of compounds comprising purines and pyrimidines, is added to the suspending medium at a final concentration of about 34-35 mg. per 100 ml. of cell suspension. A particularly effective preservative agent is adenine (6-arninopurine or a pharmaceutically acceptable acid addition salt, Mann Research Laboratories, Inc., New York, N.Y.).

The following examples are merely illustrative and are not intended to limit the invention, the scope of which is defined by the appended claims.

EXAMPLE I Group 0 blood, collected in aqueous acid citratedextrose anticoagulant, is centrifuged under sterile conditions at 2000 r.p.m. for 20 minutes. The supernatant is gently suctioned off, care being taken not to draw into the supernatant any of the red cells or bufly white layer at the interface of the red cells and supernatant. The supernatant is retained for subsequent dilution with Alsevers solution, and used as a resuspending medium.

The bufly layer (white blood cells) is carefully removed from the top of the packed red blood cells, withdrawing a thin surface of red cells if necessary. The packed red cells are washed twice with Alsevers solution, centrifuged, and stored at 2-8 C. until subsequent mixture With stabilized simulated white blood cells.

EXAMPLE II Fowl red blood cells, preferably turkey cells, are washed 4 times with saline (solution A), (centrifuged for 20 minutes at 3300 r.p.m. after each wash), and after the final wash, are resuspended as an 8% by volume suspension in saline (solution A). To 100 ml. of this 8% suspension is added 100 ml. of a 1% solution by weight of mercuric chloride in saline (solution A) and the resulting suspension is thoroughly mixed. The suspension is incubated at 37 C. for 19 hours, washed 4 times with distilled Water (centrifuging at 1200 r.p.m. for minutes after each wash), and resuspended in saline (solution A) as a 4% 4 by volume suspension. To this 4% suspension is added an equal volume of a 0.0025% weight/volume solution of tannic acid in buffered saline (solution C) and the resulting mixture thoroughly mixed, incubated at 50 C. for 30 minutes, centrifuged, and washed 3 times with distilled water.

EXAMPLE III The supernatant plasma, obtained from Group 0 bloods collected in aqueous acid citrate-dextrose anticoagulant, is diluted with 1:3 with Alsevers solution. The diluted plasma is defibrinated by adding bovine thrombin (Parke- Davis & Co., Detroit, Michigan) at a concentration of 1 unit/ml, and incubated at 37 C. for 1 hour. The clotted material is shaken vigorously to break up the clot, and filtered through a No. 50 Whatman filter pad on a Buchner funnel-suction flask set-up. Adenine sulfate is added at a concentration of 70' mgs./ 100 ml., warming at 37 C. to hasten the dissolution, and the solution filtered successively through 0.45 and 0.22 millipore filter pads.

EXAMPLE IV The method of Example III with plasma from Group AB blood in place of Group 0 plasma.

EXAMPLE V The simulated white blood cells prepared by the method of Example II are reconstituted in sterile A1- severs solution to about 24% hematocrit. This has an approximate count of 750,000-800,000 cells/mmfi. Two m1. of this suspension is further diluted by the addition of 100 ml. of the resuspending medium as prepared by the method of Example III or Example IV.

To a volume of packed human Group 0 blood cells (approximately hematocrit), prepared by the method of Example I, is added an equal volume of the diluted simulated white blood cells suspension referred to above.

The final cell suspension product, containing approximately 34-35 mg./ ml. of adenine, has a red blood cell count of about 4,000,000-5,000,000 cells/mmfi, white blood cell count of 5,000-10,000 cells/mm hemoglobin, 12-16 grams/100 ml., and hematocrit, 43-47%.

Aliquots (2.5 ml.) of the final suspension product, dispensed in glass vials, are stable for approximately 4 weeks when stored at 2-8 C.

What is claimed is:

1. A hematology control fluid comprising a suspension of fresh human red blood cells and tanned fowl red blood cells in a volume of anticoagulant-containing human serologically compatible plasma medium, approximately equal to the packed volume of said human cells at a concentration of about 5,000-l0,000 of said fowl cells per cubic millimeter.

2. The fluid of claim 1 wherein said fresh human red blood cells are Group 0 red blood cells.

3. The fluid of claim 1 wherein said tanned fowl red blood cells are turkey red blood cells.

4. The fluid of claim 1 wherein the anticoagulant in said anticoagulant-containing human plasma medium is acid citrate-dextrose solution.

5. The fluid of claim 1 wherein said plasma medium comprises defibrinated human plasma in aqueous acid citrate-dextrose anticoagulant diluted with Alsevers solution in a volume ratio of about 1:3.

6. The plasma medium of claim 5 wherein said defibrinated human plasma is Group 0 plasma.

7. The plasma medium of claim 5 wherein said defibrinated human plasma is Group AB plasma.

8. The fluid of claim 1 containing about 34-35 mg. per 100 ml. of 6-aminopurine or a pharmaceutically acceptable acid addition salt thereof.

9. The fluid of claim 1 wherein said human red blood cells are present in a concentration of about 4,000,000 to 5,000,000 cells per cubic millimeter, to provide a 6 hemoglobin level of about 12-16 grams per 100 ml. and FOREIGN PATENTS ahanlamri'tof about 43-47% 690,849 7/1964 Canada 252-408 References Cited HAROLD ANSHER, Primary Examiner UNITED STATES PATENTS 5 J. c. GIL, Assistant Examiner 3,293,134 12/1966 Lenahan et a1. 2s2F-408X 3,406,121 10/1968 Jones 252408 US. (:1. X.R. 3,412,037 11/1968 Gochman et a1. 252-408 23-230; 424-3

Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3873467 *Feb 1, 1974Mar 25, 1975United Medical Lab IncHematologic reference control
US3973913 *Jan 29, 1976Aug 10, 1976Louderback Allan LeeBlood control standard
US3977995 *Oct 17, 1974Aug 31, 1976Baxter Laboratories, Inc.Calibrating fluid for blood cell counting and hemoglobin determination
US4020006 *Aug 14, 1975Apr 26, 1977Icl/ScientificFluid containing dispersed particles simulating leukocytes and method for producing same
US4062936 *Nov 3, 1975Dec 13, 1977Mochida Seiyaku Kabushiki KaishaCarrier for immunochemical measurement
US4102810 *Mar 26, 1976Jul 25, 1978Coulter Electronics, Inc.Stabilized hematological reagent solutions
US4160644 *Jun 13, 1977Jul 10, 1979Streck Laboratories, Inc.Platelet reference control and method of preparation
US4179398 *Mar 21, 1977Dec 18, 1979ICN Medical Laboratories, Inc.Platelet control composition
US4198206 *Aug 30, 1978Apr 15, 1980Ryan Wayne LMethod for preparing a platelet reference control
US4206077 *Aug 29, 1978Jun 3, 1980Djuro RodjakAgent for facilitating the counting of thrombocytes in blood samples
US4250051 *Dec 26, 1978Feb 10, 1981Coulter Electronics, Inc.Preservative for use in calibrator compositions for blood analysis
US4282326 *Jun 22, 1979Aug 4, 1981Jeanne MoldenhauerCell culture medium supplement
US4299726 *May 7, 1979Nov 10, 1981Coulter Electronics, Inc.Process for preparing whole blood reference controls having long term stability, preconditioning diluent and media therefor
US4358394 *Aug 12, 1981Nov 9, 1982Coulter Electronics, Inc.Process for preparing whole blood reference controls having long term stability
US4579824 *May 18, 1983Apr 1, 1986Louderback Allan LeeHematology control
US4704364 *May 18, 1984Nov 3, 1987Coulter Electronics, Inc.Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems
US5039487 *May 3, 1990Aug 13, 1991Board Of Regents, The University Of Texas SystemMethods for quantifying components in liquid samples
US5380664 *Apr 17, 1990Jan 10, 1995Coulter CorporationHematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems
US5672474 *Nov 26, 1996Sep 30, 1997Streck Laboratories, Inc.White blood cell hematology control
US5677145 *Sep 25, 1996Oct 14, 1997Streck Laboratories, Inc.White blood cell hematology control
US5731205 *Jan 21, 1997Mar 24, 1998Streck Laboratories, Inc.White blood cell hematology control
US5981282 *Jan 21, 1997Nov 9, 1999Streck Laboratories, Inc.White blood cell hematology control
US5994139 *Apr 7, 1998Nov 30, 1999Coulter International Corp.Stable hematology control composition and method of use
US6200500Aug 20, 1999Mar 13, 2001Streck Laboratories, Inc.Hematology control and system for multi-parameter hematology measurements
US6221668Feb 16, 2000Apr 24, 2001Streck Laboratories, Inc.Hematology control and system for multi-parameter hematology measurements
US6362003 *Sep 14, 1998Mar 26, 2002Coulter CorporationHematological reference control composition containing leukocyte analogs, methods of making, and uses thereof
US6399388Dec 19, 2000Jun 4, 2002Streck Laboratories, Inc.Hematology control and system for multi-parameter hematology measurements
US6403377Aug 21, 2001Jun 11, 2002Streck Laboratories, Inc.Hematology control and system for multi-parameter hematology measurements
US6406915Aug 21, 2001Jun 18, 2002Streck Laboratoreis, Inc.Hematology control and system for multi-parameter hematology measurements
US6653137Dec 3, 2001Nov 25, 2003Streck Laboratories Inc.Hematology reference control
US6723563Dec 3, 2001Apr 20, 2004Streck Laboratories Inc.Hematology reference control
US20050048656 *Aug 2, 2004Mar 3, 2005Young Carole J.Quality control method
US20050048657 *Aug 2, 2004Mar 3, 2005Young Carole J.Method of using a hematology control product
US20050095719 *Nov 24, 2004May 5, 2005Young Carole J.Quality control method
US20050221496 *May 25, 2005Oct 6, 2005Young Carole JQuality control method
US20050221497 *May 25, 2005Oct 6, 2005Carole YoungQuality control method
DE3017152A1 *May 5, 1980Nov 27, 1980Coulter ElectronicsMittel fuer die herstellung einer blut-vergleichsueberwachung, verfahren zu ihrer herstellung und verduennung hierfuer
EP0001741A1 *Aug 28, 1978May 16, 1979Walter Sarstedt Kunststoff-SpritzgusswerkMeans to facilitate blood platelet counting in blood samples
WO1985005450A1 *May 7, 1985Dec 5, 1985Coulter Electronics, Inc.Hematology control compositions for three populations of leukocytes: and methods for their preparation and use in whole blood control systems
Classifications
U.S. Classification436/10, 436/16
International ClassificationG01N33/96
Cooperative ClassificationG01N33/96, G01N2496/05
European ClassificationG01N33/96
Legal Events
DateCodeEventDescription
May 14, 1981ASAssignment
Owner name: WARNER-LAMBERT COMPANY, 201 TABOR RD., MORRIS PLAI
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:PFIZER INC.;REEL/FRAME:003853/0905
Effective date: 19810409